No Data
No Data
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm With SOD2 MRNA Delivered by SemaPhore Nanoparticles
Study shows significant reduction in aorta dilation, delayed rupture and lower mortality in established animal model of abdominal aortic aneurysm
Express News | Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm With Sod2 Mrna Delivered by Semaphore Nanoparticles
Altamira Therapeutics | 20-F/A: Registration statement / Annual report / Transition report (Amendment)
Express News | Altamira Therapeutics Highlights Review Article Published On Use Of Betahistine In Vertigo Management
Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
Hamilton, Bermuda, June 20, 2024 (GLOBE NEWSWIRE) -- Independent review discusses evidence supporting the use of betahistine to alleviate residual dizziness following physical repositioning procedur
Express News | Altamira Therapeutics Ltd - Merged Entity Will Be Called Altamira Therapeutics AG and Continue to Serve as Core Operating Subsidiary of Company
No Data